Last reviewed · How we verify

NCT05075603

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Completed Phase 1 Last updated 23 October 2025
What this trial tests

Phase 1 trial testing Efineptakin alfa in Refractory Diffuse Large B-cell Lymphoma in 17 participants. Completed in 12 March 2025.

Timeline
6 August 2021
Primary endpoint
18 December 2024
12 March 2025

Quick facts

Lead sponsorNeoImmuneTech
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment17
Start date6 August 2021
Primary completion18 December 2024
Estimated completion12 March 2025
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

NeoImmuneTech — full company profile →

Who can join

18 and older, any sex, with Refractory Diffuse Large B-cell Lymphoma or Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Nanodelivery of nucleic acids.
    Mendes BB, Conniot J, Avital A, Yao D, et al · · 2022 · cited 401× · PMID 35480987 · DOI 10.1038/s43586-022-00104-y
  2. CAR-T cell therapy for cancer: current challenges and future directions.
    Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w
  3. The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy.
    Wang C, Kong L, Kim S, Lee S, et al · · 2022 · cited 78× · PMID 36142322 · DOI 10.3390/ijms231810412
  4. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
    Kim MY, Jayasinghe R, Devenport JM, Ritchey JK, et al · · 2022 · cited 77× · PMID 35697686 · DOI 10.1038/s41467-022-30860-0
  5. The application of Interleukin-2 family cytokines in tumor immunotherapy research.
    Zhou Y, Quan G, Liu Y, Shi N, et al · · 2023 · cited 32× · PMID 36936961 · DOI 10.3389/fimmu.2023.1090311
  6. An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
    Xiang J, Devenport JM, Carter AJ, Staser KW, et al · · 2023 · cited 29× · PMID 37798328 · DOI 10.1038/s41375-023-02039-z
  7. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
    O'Neal J, Cooper ML, Ritchey JK, Gladney S, et al · · 2023 · cited 22× · PMID 37399471 · DOI 10.1182/bloodadvances.2023010032
  8. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
    Xiao X, Wang Y, Zou Z, Yang Y, et al · · 2022 · cited 20× · PMID 36091028 · DOI 10.3389/fimmu.2022.954235

Verify or expand the search:

Other trials of Efineptakin alfa

Trials testing the same drug.

Other recruiting trials for Refractory Diffuse Large B-cell Lymphoma

Currently open trials in the same condition.

Other NeoImmuneTech trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing